Ideas to action: independent research for global prosperity
Research
Innovative, independent, peer-reviewed. Explore the latest economic research and policy proposals from CGD’s global development experts.
POLICY PAPERS
May 09, 2024
CGD NOTES
May 07, 2024
WORKING PAPERS
April 23, 2024
WORKING PAPERS
May 01, 2024
All Research
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Publication Type
Facet Toggle
Time Frame
Facet Toggle
Research
CGD NOTES
May 07, 2024
IDA faces many headwinds—difficult aid politics in key donor countries; a high-interest rate environment that renders its financial model less efficient; and deteriorating credit quality in many of its client countries that makes risk taking less appealing. Breaking the $100 billion mark is not a po...
CGD NOTES
April 11, 2024
The reform agenda is long and complicated. MDB shareholders, managers, and other stakeholders need a systematic way to assess progress as objectively and independently as possible. CGD has built this MDB reform tracker for this purpose. The aim is a comprehensive tool, but also a focus on reform pro...
CGD NOTES
June 16, 2023
In this note we assess the potential short-term fiscal impact of these instruments. We look at three major natural disasters over the past two years and assess how much relief each country would have received if DSCs had been included in the totality of their external debt instruments.
CGD NOTES
June 07, 2023
PM-JAY, India’s national health insurance program, is the largest publicly funded health insurance program in the world. It has reformed the way in which the poor and vulnerable access hospital care in India. The size of this program and the inclusion of private providers in delivering care has led ...
CGD NOTES
March 01, 2023
The World Bank is in the most visible position as it works on its evolution roadmap. But change is needed across the MDB system to enable these institutions to play a more effective and a much bigger role in helping the world meet these challenges. Together they hold about $500 billion in shareholde...
CGD NOTES
December 14, 2022
Almost a year after two oral antiviral treatments received emergency use authorization, demand is extremely low. In this note, we argue that governments and their donor partners should use data and evidence to consider the economic and clinical rationale for registering, financing, purchasing, and d...